MacroGenics (MGNX) anticipates that its cash, cash equivalents and marketable securities balance of $140.4M as of June 30, plus the $100.M in milestones subsequently received from Incyte (INCY), in addition to projected and anticipated future payments from partners and product revenues should support its cash runway into 2026. The company’s expected funding requirements reflect anticipated expenditures related to the Phase 2 TAMARACK clinical trial, the Phase 2 LORIKEET study as well as MacroGenics’ other ongoing clinical and preclinical studies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Incyte price target raised to $66 from $61 at RBC Capital
- Incyte price target raised to $88 from $80 at Citi
- Incyte price target raised to $66 from $62 at BofA
- MacroGenics gets $100M in milestone payments from Incyte for Zynyz development
- Incyte raises FY24 Jakafi net product revenues to $2.71B – $2.75B